Abstract
When we think of cardiac affection in the context of systemic lupus erythematosus (SLE), we usually refer to pericarditis first. As frequent as this affection is, it is actually not the only cardio-vascular problem that occurs with this systemic inflammatory disease. Are the cardiac events--ranging from multiple heart valve involvements to increased cardiovascular risks--clinically significant? And are they involving a specific follow-up, treatment or support? We are therefore trying to evaluate these questions in order to give some recommendations to any practitioners following up a lupus patient, or a patient suffering from any other inflammatory systemic disease.
Publication types
-
Case Reports
-
English Abstract
MeSH terms
-
Adult
-
Antibodies, Antinuclear / blood
-
Aortic Valve Insufficiency / diagnosis
-
Aortic Valve Insufficiency / etiology
-
Biomarkers / blood
-
Cardiovascular Diseases / blood
-
Cardiovascular Diseases / diagnosis*
-
Cardiovascular Diseases / drug therapy
-
Cardiovascular Diseases / etiology*
-
Cardiovascular Diseases / immunology
-
Diagnosis, Differential
-
Female
-
Glucocorticoids / therapeutic use
-
Humans
-
Lupus Erythematosus, Systemic / blood
-
Lupus Erythematosus, Systemic / complications*
-
Lupus Erythematosus, Systemic / diagnosis*
-
Lupus Erythematosus, Systemic / drug therapy
-
Lupus Erythematosus, Systemic / immunology
-
Myocarditis / diagnosis
-
Myocarditis / etiology
-
Pericarditis / diagnosis
-
Pericarditis / etiology
-
Practice Guidelines as Topic
-
Treatment Outcome
Substances
-
Antibodies, Antinuclear
-
Biomarkers
-
Glucocorticoids